Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 4, 1998

View Archived Issues

A reduced deacetylated metabolite of FK-317 is responsible for antitumor activity

Coadministration of PNU-156765 and antiandrogen for prostate cancer

Omapatrilat effective therapy for patients with chronic heart failure

IND application for NeXstar antiangiogenesis drug approved by FDA

MacroChem's treatment for erectile dysfunction demonstrates safety and efficacy

Muse in combination with Actis in the treatment of male impotence

Regeneron receives milestone payment from Sumitomo related to BDNF development

Sonus files amendment to EchoGen NDA

NK2 antagonist saredutant prevents NKA-induced bronchoconstriction in asthmatic subjects

FDA approves Gemzar for first-line treatment of non-small cell lung cancer

Clinical trials commence for Calydon's viral therapeutic for prostate cancer

Biotech Australia announces encouraging early clinical trial results with leg ulcer treatment

Neuroprotective and antioxidant phenazines designed at Nippon Chemiphar

Antimicrobial polypeptides claimed by Fujisawa for infectious diseases

P&U, U of Maryland describe inhibitors of kynurenine aminotransferase

Scripps patents guanine derivatives with immunostimulating activity

Genetix awarded grant for antiangiogenic gene therapy development

Cortech to form new European company to develop PSI technology

FDA clears Intron A for pediatric chronic hepatitis B

Label expansion recommended for Photofrin in U.S.

Spotlight on treatment of substance abuse disorders

Taisho discovers potent and selective CRF1 receptor antagonists with anxiolytic effects

Potent mixed delta/mu-opioid agonist identified by Glaxo Wellcome/Delta team

Merck KGaA synthesizes new PDE V inhibitor with potential for treating ED

DW-2282: active enantiomer of DW-2143 and potent antitumor agent

Alprostadil alfadex is a promising treatment for ED

LLPGE1 evaluated in pilot study; findings will be applied to future studies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...